CRBP
HEALTHCARECorbus Pharmaceuticals Holdings Inc
$10.92+0.25 (+2.34%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CRBP Today?
No stock-specific AI insight has been generated for CRBP yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.33$20.56
$10.92
Fundamentals
Market Cap$194M
P/E Ratio—
EPS$-5.90
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume630K
Avg Volume (10D)—
Shares Outstanding17.7M
CRBP News
20 articles- Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026Yahoo Finance·May 5, 2026
- Spotify upgraded, Alibaba initiated: Wall Street's top analyst callsYahoo Finance·Apr 29, 2026
- Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701Yahoo Finance·Apr 22, 2026
- Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash ValueYahoo Finance·Apr 17, 2026
- Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for ObesityYahoo Finance·Apr 14, 2026
- Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical CancerYahoo Finance·Apr 7, 2026
- Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health SummitYahoo Finance·Mar 18, 2026
- How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%Yahoo Finance·Mar 11, 2026
- Corbus Pharmaceuticals: Q4 Earnings SnapshotYahoo Finance·Mar 9, 2026
- Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate UpdateYahoo Finance·Mar 9, 2026
- Corbus Pharmaceuticals Touts “Catalyst-Rich” 2026 With CRB-701 and CRB-913 Data Readouts AheadMarketbeat·Feb 26, 2026
- Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences ConferenceYahoo Finance·Feb 12, 2026
- Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 5, 2026
- While hedge funds own 24% of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), retail investors are its largest shareholders with 46% ownershipYahoo Finance·Dec 27, 2025
- Corbus Pharmaceuticals Reports Phase 1a Obesity Drug Data Showing Weight LossYahoo Finance·Dec 11, 2025
- Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight LossYahoo Finance·Dec 11, 2025
- Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025Yahoo Finance·Dec 10, 2025
- Corbus Pharmaceuticals: Q3 Earnings SnapshotYahoo Finance·Nov 12, 2025
- Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate UpdateYahoo Finance·Nov 12, 2025
- Corbus Pharmaceuticals to Participate in Upcoming Investor ConferencesYahoo Finance·Nov 6, 2025
All 20 articles loaded
Price Data
Open$10.67
Previous Close$10.67
Day High$11.36
Day Low$10.51
52 Week High$20.56
52 Week Low$6.33
52-Week Range
$6.33$20.56
$10.92
Fundamentals
Market Cap$194M
P/E Ratio—
EPS$-5.90
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume630K
Avg Volume (10D)—
Shares Outstanding17.7M
About Corbus Pharmaceuticals Holdings Inc
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. The company is headquartered in Norwood, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—